British Journal of Pharmacology

Cover image for Vol. 174 Issue 7

Editor-in-Chief: Professor A. Ahluwalia

Impact Factor: 5.259

ISI Journal Citation Reports © Ranking: 2015: 17/255 (Pharmacology & Pharmacy)

Online ISSN: 1476-5381

Associated Title(s): British Journal of Clinical Pharmacology, Pharmacology Research & Perspectives


Author Guidelines


You will find here the full British Journal of Pharmacology (BJP) Author Guidelines

Useful links for Authors:

Submission website

New BJP reporting policies

Approved Abbreviations List

Preparing artwork: guidance

BJP Publication Ethics Policy

Declaration of Transparency and Scientific Rigour - in English

Declaration of Transparency and Scientific Rigour - in Chinese

BJP Author Guidelines as a PDF



Author Guidelines


All successful BJP authors (and co-authors) can nominate up to 10 colleagues to receive their final article or review, as a PDF, via an automated process within the journal’s Author Services system.

All successful authors will also be invited to join Kudos, to assist with enhancing the value of their research.

SCOPE AND TYPES OF ARTICLES PUBLISHED BY BJP

BJP publishes research papers, review articles, commentaries and letters to the Editor. Review articles are normally commissioned, but consideration will be given to unsolicited contributions. BJP welcomes contributions in all fields of pharmacology. The work should have a direct bearing on the effects, mechanisms or uses of drugs, or the development of new drug targets.. In addition, BJP welcomes studies assessing the impact of the effects and mechanisms of drugs acting upon the microbiome, including studies assessing novel probiotic and prebiotic interventions.

Commentaries are invited by the Editor-in-Chief on articles published in the journal.

Letters to the Editor are acceptable where they are a comment on a paper published in the journal or relate to current issues pertinent to the field of Pharmacology.

BJP does not publish work on the actions of biological extracts of unknown chemical composition (e.g. unpurified and unvalidated) or unknown concentration. Papers that involve investigations on tobacco, smoking, alcohol, cocaine and other substances of abuse, whether directly or in the context of their use to generate a disease model (eg smoking for pulmonary disease), will be considered on scientific merit (which includes ethical justification) and relevance to pharmacology.

GENERAL INSTRUCTIONS FOR PREPARING ALL ARTICLE TYPES

Use Times New Roman, font size 12, 1.5 spacing.

Language and style

Be succinct. Stay ‘on topic’. Avoid unsubstantiated speculation. Don’t assume mechanisms when using drugs as tools – selectivity is concentration-dependent. Use correct, clear, plain English.

Help for Authors

For help with designing your experiments, please see the new NC3Rs Experimental Design Assistant.

BJP employs Press Editors and Copy Editors, who provide a free language and copy-editing service to improve the quality of all manuscripts that are acceptable for publication on scientific grounds.

Moreover, a pre-acceptance Editing Service (comprising English language editing, translation services, manuscript formatting and figure preparation) is available and can provide you with expert help to ensure your manuscript is ready for submission. Japanese authors can also find a list of local English improvement services at http://www.wiley.co.jp/journals/editcontribute.html . All services are paid for and arranged by the Author, and use of one of these services does not guarantee acceptance or preference for publication.

Tips for authors on how to navigate the peer review process can be found here.

Instructions for preparing specific article types

Research papers

  • Supply a structured abstract of no more than 250 words.
  • Please submit no more than a combined maximum of ten (10) figures and tables.
  • Research papers should be no more than 4,000 words.
    • ‘Methods’ should not be included in the word count.
    • The Discussion and Conclusions should be a maximum of 1,500 words.
  • References: No more than 60.
  • Scope should be pharmacological, i.e. focus on drugs and/or drug targets by characterising novel effects or mechanisms, or by validating new analytical approaches, methods or models and must constitute a significant contribution to pharmacological knowledge. Papers that reassess pharmacological concepts based on earlier results, and purely theoretical papers, will be considered. Papers describing new methods in pharmacology that embody new principles are also welcome.

Review articles

  • Review articles must be no more than 5,000 words (excluding reference and figure legends).
  • Supply a non-structured Abstract of no more than 250 words.
  • There should be a minimum of two figures that summarise the major findings discussed.
  • There should be no more than a combined maximum of five additional figures and tables (combined).
  • The use of explanatory figures in the form of cartoons, flow diagrams, etc. is encouraged.
  • Professional assistance with diagrams can be provided for review articles on request.
  • Authors should break up their review into headed sections.

Un-commissioned review will undergo a preliminary Editorial decision.

Authors of unsolicited reviews must submit them directly to ScholarOne, following the standard submission procedure.

Letters to the Editor

Any correspondence is limited to specific comments or responses relating to a recent BJP paper, the authors of which will be invited to reply. Criteria for Letters to the Editor are as follows: no abstract or any internal structuring; fewer than 800 words; no figures; fewer than 5 references; no new or unreviewed data

Commentaries

Criteria for commentaries are as follows: no abstract; fewer than 1200 words; no figures; fewer than 5 references; there should be no new or unreview data and no internal sectioning.

Manuscripts should be submitted via the Scholar One (S1) Website in the form of a Word document. Submission is now accomplished by uploading a single Word document, which should follow the sequence laid out below in these Author Guidelines.

BJP has strict requirements for reporting experimental design, statistical analysis and experiments involving animals or animal tissue. See editorialsMcGrath & Lilley, (2015) and Curtis et al., 2015.

MANUSCRIPT PREPARATION AND SUBMISSION

For submission you will be asked to write your manuscript in a Word document in the sequence recommended below.

The Word document should consist of

  • Title page
  • Abstract (structured)
  • Introduction
  • Methods
  • Results
  • Discussion
  • Author contributions
  • Acknowledgments
  • References
  • Figures and figure legends
  • Tables (if applicable).

Word Limit

To facilitate complete transparency and reproducibility, “Methods” will not be included in the word count: the text in the remainder of the manuscript should contain no more than 4000 words (it should, however, be as succinct as possible). Legends to figures and tables are excluded from this limit.

Units and Symbols

SI units and symbols should be used. Negative index notation (e.g. mg kg−1, pmol mm−2 min−1) should be used rather than solidus notation (e.g. mg/kg, pmol/mm2/min). ‘dL’ is not an SI unit; this is the most common mistake.

Should you have any queries regarding preparation of your manuscript, its submission or the peer review process, please do not hesitate to contact us at BJPedoffice@wiley.com.

SUMMARY OF SUBMISSION REQUIREMENTS

TITLE

Your title should not exceed 150 characters (including spaces). Please optimise your title for search engines.

  • The Title must clearly indicate the subject matter of the paper, why the work is important and any assertions it contains must be justified by the results presented in the paper. Cumbersome chemical names, technical details, and unfamiliar abbreviations should be avoided in the title.
  • On the Title page (only), if you are using author initials and not full names, include spaces in between an author's initials, e.g. ‘A E Smith’. If an author's initials do not appear on the title page of your manuscript according to these guidelines, there may be a delay or error in archiving in PubMed.

RUNNING (SHORT) TITLE

Please supply a short title of no more than 60 characters, which will be used as the running head of your paper.

AUTHOR INFORMATION

For each author, please supply

  • Full name
  • Full institutional affiliation
  • The Contribution of that author to the paper (please see guidance on authorship and contribution in the Journal’s Ethics Policy. (In a nutshell, authors must have made a real contribution to the paper and must fulfil all four ICJME authorship criteria.)

ABSTRACT

Your Abstract should convey clearly the key messages of the work, and why the work is important.

It should not exceed 250 words (including subheadings). For Research Articles, the Abstract must be structured as follows:

  • Background and Purpose
  • Experimental Approach
  • Key Results
  • Conclusion and Implications.

Minimise abbreviations (see more below) and do not include any references.

NON-APPROVED ABBREVIATIONS

There is a list of Approved Abbreviations that do not need to be defined in the manuscript or abstract. All other abbreviations must be defined here, as an alphabetical list, and when first used in the text.

PHARMACOLOGICAL NOMENCLATURE

Nomenclature used in your article should follow that of the IUPHAR/BPS Guide to PHARMACOLOGY. Should your manuscript be accepted, the main pharmacological targets discussed in your manuscript will ultimately be highlighted in your published article. Until the end of February 2017, the main pharmacological targets should be presented as two tables of links (for targets and ligands).

From March 1st 2017, however, you will be asked to apply linking to these ligands and targets within the body of your manuscript. You will also be asked to provide a simple list of ligands and targets you have hyperlinked so that the press editors can check you have included all major targets. This list will not be published.

You will also be asked to supply a standard ‘ ‘Nomenclature of Targets and Ligands’ statement.

You are not required to supply these items at submission, this will be requested should your manuscript move forward in the review process. You will be given full and clear instructions on how to fulfill these requirements by the editorial office. Please see more below, within the section ‘FURTHER INFORMATION’.

ACKNOWLEDGEMENTS: FUNDING STATEMENT

Where there has been funding or financial support, authors must publish a statement in the Acknowledgements section. Please see below for guidance.

CONFLICTS OF INTEREST STATEMENT

All papers publish a Conflicts of Interest statement. Please see below for guidance.

TABLES, FIGURES AND LEGENDS

Please state the numbers of figures and of tables submitted as part of your manuscript.

Please note

  • Reviews: There should be a minimum of two figures that summarise the major findings discussed. There should be no more than a maximum of five additional figures or tables.
  • Research articles: There should be a combined maximum of ten figures and tables.
  • Each figure and table should be embedded in the manuscript or placed at the end of the manuscript. You do not need to upload them individually on initial submission. If your manuscript moves forward through the review process you will be asked to upload figures individually as separate files at the first revision stage.
  • Non-essential figures and tables can and should be added as supporting information.

SUPPORTING INFORMATION

BJP does not accept 'unpublished data' or 'data not shown'. All data that is essential for a manuscript should be contained within the main document. However, any additional data that provides supplementary information that aids interpretation such as demonstrations of selectivity of an antibody, demographic data of animal or human cohort, typical western blots or immunohistochemical images should be submitted as supporting information, with an explanation of why it is considered supporting, rather than essential to the paper. Please state the number of figures and tables submitted as supporting information (including zero - please add 'None supplied' ).

What is supporting information?

Supporting information is peer-reviewed material directly relevant but not essential to the conclusion of an article, such as control experiments, supporting data tables or movies. The article must be complete and self-explanatory without this additional information. It is not edited, so before submission, consider carefully how any additional data supports the paper.

File sizes must be as small as possible, so that they can be downloaded quickly, so please submit supporting information as PDFs where possible. When not possible, accepted formats are HTML files (.html), movie files (.mov/.mpg), and audio files (.wav/.mp3/.wma).

Supporting data for an article appears in the Supporting information section of both the html and PDF version of an article on the journal website; it is accessible via a hyperlink and can be downloaded separately.

Open data

BJP supports authors who wish to publish their raw data in open repositories. Please include any details on this with your submission.

MANUSCRIPT PREPARATION

INTRODUCTION

In the Introduction state the background to your work and its purpose. State your hypothesis and questions asked. Provide only essential background. 500 words is generally more than sufficient.

METHODS

To facilitate complete transparency, ‘Methods’ will not be included in the word count of Research Articles.

Your Methods must be described in sufficient detail to allow the experiments to be interpreted and repeated by an experienced investigator. Where published methods are used, references should be given, together with a brief outline: any references must provide the full description and not be a signpost to another reference. If this is a problem please provide the full description of the method in your own manuscript.

For experimental studies, the methods should be presented in sections and should cover

  • Test systems used (animal preparations, isolated tissues, cultured cells, in vitro systems, etc.) and the measurements made (with technical details) for each system;
  • Where animals have been used as a test system the Journal has strict requirements for the reporting of experiments involving animals or animal tissue (adherence to ARRIVE and BJP guidelines should be stated in this section).
  • Experimental protocols and design (adherence to BJP guidelines should be stated in this section).
  • Data and statistical analysis
  • Materials.

For all studies, experimental design, data analysis and statistical procedures should be consistent with the principles explained in the editorial Experimental design and analysis and their reporting: new guidance for publication in BJP, and the major points detailed below. (For a precise bullet list, please see the Declaration of Transparency and Scientific Rigour.)

Authors should ensure that for each test system used the following information is provided within the methods. Authors should follow the guidance provided at the bullets.

For the rationale, please read Curtis et al., 2015.

Group sizes

  • Explain how you have determined/designed group sizes. These should be equal by design, and any variation owing to experimental losses or violation of predetermined exclusion criteria must be explained.
  • BJP accepts the use of post-hoc statistical tests designed to identify outliers within datasets. These tests should be appropriate for the type (distribution) of data being analysed. Examples of such tests include Grubb’s or ROUT outlier tests. Where outliers are identified a clear indication of number of data points excluded must be provided with a robust explanation for the type of test used.
  • The principle is that you should provide the exact group size (n) for each experimental group/condition, not a range; and n refers to independent values, not replicates. Data subjected to statistical analysis should have a group size (n) ≥ 5. If n is less than 5 anywhere in the study, please provide an explanation, and please do not undertake statistical analysis of the dataset.

Randomisation

  • Please state whether animals or human subjects were randomised for treatment. If randomisation was not carried out, state that randomisation was not used, and please supply an explanation for why not.

Blinding

  • Please state whether how the operator and data analysis were blinded. If blinding was not undertaken, or not feasible, please state why.

Normalisation

  • When normalisation is employed (e.g. expression of values as ‘% of baseline’ or ‘fold mean control’) please provide a valid scientific justification (i.e. to control for unwanted sources of variation).
  • If employing normalisation that generates control or baseline values with no variance (SEM = 0), please explain with a valid scientific justification and do not subject such data to parametric statistical analysis.
  • Please explain any data transformation (such as log transformation) with a valid scientific justification (i.e. to generate a Gaussian-distributed data set amenable to parametric analysis).

Data and Statistical analysis

  • This section is mandatory in all manuscripts and should include the statement that ‘the data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015).’
  • Provide details of any statistical package or program employed, including manufacturer and model number and details of which tests (and which options) and which program(s) (with full version number) were used.
  • If an experiment (e.g. assay) is undertaken in duplicate, triplicate etc., please state that technical replicates were used to ensure the reliability of single values. This reliability can be quoted as a coefficient of variation. In data analysis and data presentation use the single values (i.e. 5 samples each run in triplicate is n=5 not n=15).

When comparing groups, and if a level of probability (P) is deemed to constitute the threshold for statistical significance, define this here in Methods, and do not vary it later in Results (by presentation of multiple levels of significance). Thus if P<0.05 is defined as threshold, P<0.01 etc. should not appear in the results. However, setting P at a lower value such as P<0.01 or 0.001 is quite acceptable, provided that this is defined as constituting statistical significance, and is not varied. It is not necessary to state the exact level of P.

Studies employing animals, animal tissues or primary cultures from animal tissues must provide additional detail covering the requirements for reporting experiments involving animals or animal tissue, as detailed below.

Requirements for reporting experiments involving animals or animal tissue

This information is required only if animals, animal tissue or primary cultures are involved. It allows you to comply with BJP Policy on reporting experiments involving animals and with the principles of ARRIVE and the United States NIH. Please ensure that this section contains the details described as follows.

Enter the general principles that you followed in this section. You may already have put some details in the main section of Methods, and we apologise for the duplication. Please do not worry about minor repetition.

Validity of animal species or model selection

  • Provide a scientific justification for the animal species and each model selected for study. For instance, ‘this model of pain in rats has been in use for several years (reference)’ (refer to review on pain models).

Ethical statement

  • Make a statement of ethical approval for experimentation that will be recognised worldwide. Indicate the nature of the ethical review permissions, and national or institutional guidelines for the care and use of animals, that cover the research. Include application approval numbers and web addresses of the approving organisations, if available.

For further details, please see the Ethics Section below.

Animals

  • Please note source, species, strain, sex, age range, weight and any additional data that are relevant to the study.

Housing and husbandry

  • Standard animal housing and care does not need to be explained in detail as long as these meet the standards required by relevant local guidance or law
  • Provide details of non-standard housing (type of facility e.g. specific pathogen free [SPF]; type of cage or housing; bedding material; number of cage companions; tank shape and material etc. for fish).

Experimental procedures

Provide details, as appropriate, of behavioural tests, anaesthesia and analgesia, surgical procedures, how the animal was killed and, if there is recovery following surgery, the methods of asepsis, and post-operative care. Include welfare-related assessments, measurements and interventions (e.g. humane end points) that were carried out prior to, during, or after the experiment.

Materials

  • Finally, please end your Methods section with the Materials sub-section. Provide the suppliers (names and addresses) of drugs and other chemicals, reagents and other materials.
  • For new compounds, the synthesis and physicochemical characteristics of the compound(s) must be summarised here unless these have already been published in another journal or in a patent.
  • Please note BJP will not consider manuscripts concerning or using compounds of undisclosed structure or undefined mixtures of compounds e.g. plant extracts.

RESULTS

In this section, please do not repeat numerical values of any data presented in tables or figures. Each value should be shown EITHER in the Tables or Figures OR in the text, NOT both. When a change is statistically significant, there is no need to show P<0.05 etc. in the text, as this level will have already been given in the Methods (data analysis) and ONLY ONE VALUE of P should be used throughout the manuscript.

Do not interpret, compare or discuss the data reported in the Results section; it is more appropriate to do this in the Discussion and Conclusions.

DISCUSSION AND CONCLUSIONS

Please note this section is normally restricted to 1,500 words and Senior Editors will ask for justification when this limit is exceeded.

Explain how your hypothesis or initial questions have been addressed by your results and why this is important.

Make a statement concerning the possible clinical relevance of the study.

If your study has any implications for the 3Rs (replacement, refinement or reduction), please make a statement on this in the Discussion, e.g. ‘When used in signalling assays, the above procedure results in one rat pup yielding approximately 8 data points for neurons and 24 data points for glia. This is a significant enhancement over previous studies examining cAMP signalling, where approximately two rat pups have yielded a single data point for trigeminal ganglia-derived neurons’ (Walker et al., British Journal of Pharmacology. 2014)

REFERENCES

The number of references for a Research paper is normally no more than 60. Editors may ask for reduction of references when this limit is exceeded.

Use Harvard style.

In the text, references to other work should take the form ‘(Connor and Kitchen, 2006)’ or ‘Connor and Kitchen (2006) showed that…’. For more than six authors, it is ‘Zamora et al. 2006 showed…’ Reference to ‘unpublished observations’ or ‘personal communications’ should not be included in the list of references and in general should be avoided (because they cannot be verified). Papers in preparation or those that have been submitted but not yet accepted for publication must not be included in the list of references.

In the reference list, arrange alphabetically according to the surname of the first author, and include the following crucial information: journal title, author surnames and initials, year of publication, volume and page numbers - or DOI (digital object identifier) number if a paper is in press and not yet published in an issue (please see example below). When the surnames of first authors are identical, the alphabetical order of the surnames of subsequent authors takes precedence over the year of publication. If more than one paper by the same authors in one year is cited, ‘a’, ‘b’, ‘c’, etc. are placed after the year of publication, both in the text and in the list of references. All authors should be quoted for papers with up to six authors; for more than six authors, quote the first six followed by ‘et al.’. Please see examples below.

Follow these examples but do not worry about minor variations introduced by your source of references, such as punctuation, as long as the essential elements are present.

Journal Reference:

Connor M, Kitchen I (2006). Has the sun set on κ3-opioid receptors? Br J Pharmacol 147: 349–350.

Journal Reference: Early View or Accepted Article :

van Goethem NP, Schreiber R, Newman-Tancredi A, Varney M, Prickaerts J (2015). Divergent effects of the ‘biased’ 5-HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task. Br J Pharmacol. DOI: 10.1111/bph.13071.

Book Reference :

Meesmann W (1982). Early arrhythmias and primary ventricular fibrillation after acute myocardial ischaemia in relation to pre-existing coronary collaterals. In Early arrhythmias resulting from myocardial ischaemia. Ed Parratt, JR McMillan: London, pp 93–112.

E-book Reference:

Sadler P (2003). Strategic Management. [Online] Sterling. VA Kogan Page. Available from: http://www.netlibrary.com/reader/. [Accessed: 6th May 2015].

Meeting Abstract Reference :

Wenger TL, Lederman SN & Strauss HC (1985). Effects of flecainide in dogs with coronary occlusion and reperfusion. Circulation, 72 (suppl. III):225.

Website Reference :

Links to websites may be included in manuscripts, but these links must, where possible, terminate on a permanent data repository, such as those of the host platforms used by the journals. Links to private author's web pages/sites are not permitted. The text accompanying links should be constructed so that in the event of link failure the text can be used in a search engine to locate the website. For links to databases that are not permanent repositories please cite the date of access.

IUPHAR/BPS Guide to Pharmacology . [Online] Available from http://www.guidetopharmacology.org/). [Accessed: 9th May 2015].

Equivalent Permanent Repository:

Alexander SPH, Benson HE, Faccenda E, Pawson A J, Sharman JL, McGrath JC, et al. (2015), The Concise Guide to PHARMACOLOGY 2015/16: Overview. Brit J Pharmacol, 172: 5729–5743. doi: 10.1111/bph.13347

Data Archive Reference :

Brown LJ (20XX). Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI).

Other (e.g. government guideline) :

FDA (2002). ICH Draft Consensus Guideline, S7B Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals: US Department of Health and Human Services.

TABLES, FIGURES AND LEGENDS

Figures and Tables can be embedded in your manuscript at the appropriate point or placed at the end of the paper. They should be uploaded as separate files to Scholar One only on revision. Figure legends should go below each Figure and Table titles should be at the top of each Table. (If you find embedding complicated, after the references simply place all the Tables with their associated legends first, followed by the Figure Legends in one sheet and then the figures.)

Non-critical data, e.g., structure of primers, should be put in a supplementary file and submitted as supporting information (see below) rather than as figures or tables in the manuscript.

Figures

To avoid unnecessary figures, only critical data should be presented in the figures. Non-critical data (e.g. positive /negative controls) should be put in a supporting file and submitted as supporting information.

Figures should be numbered consecutively with Arabic numerals and may comprise several parts (Fig 2A, 2B, 2C etc.). Authors must ensure that all parts are fully legible including lettering in the labels of axes or data sets, when the figure is printed to a maximum of A4 page size.

Keys to the different symbols, bars and lines should be placed in the whole figure and not repeated in the legend.

Figure Legends

A legend should be provided for each figure. Figure legends should be placed below each figure if embedded or in a list just prior to the figures themselves if placed at the end of the manuscript. These legends should include a brief title to indicate the content of the figure.

Abbreviations may be used in the figure (e.g. for drug treatments) but must be explained in the legend. Approved abbreviations or abbreviations already defined in the manuscript are permitted.

Tables

Each Table needs a title, which appears above the Table, and a footnote, which appears below the Table. The title should describe briefly the content of the Table. The footnote explains the characteristics of the data shown, such as treatment groups, times of sampling, numbers of samples, along with significant differences, statistical methods used. Tables should be self-explanatory and should be numbered consecutively with Arabic numerals. The number (‘Table X’) should be followed by a short title (‘Effect of Y on haemodynamics’’), occupying not more than two lines, at the head of the table. Any necessary explanations of the nature of values (e.g. % or mean ± SEM, * P < 0.05, compared with what, etc.) and the sources of any material not your own, or material published elsewhere should be placed in a Footnote, which will appear below the Table. Use superscript letters (not symbols) for callouts from the Table, e.g. data from another publication, and a single symbol (*, #, † etc.) to show significant effects.

Technical guidance on tables and figures:

  • Save line art such as charts, graphs and illustrations in EPS format.
  • Save photographic images in TIFF format.
  • Save figures containing a combination of photographic images and text (eg annotated photographic images with text labels) as EPS.
  • For large file sizes, zip or save in another compressed format such as .rar to reduce the file size.
  • Resolution for all illustrations (graphs, annotated artwork, micrographs and photographs) must be 300 dpi.
  • Use hatching rather than shading in graphs.
  • Use colour only if it enhances the clarity of figures. The meaning of the figure must remain clear even if viewed in black and white.
  • If using colour pairs, blue/yellow is preferable to red/green.
  • Text and labelling in standard fonts at 8-10 point font size; Line Width at 0.3 to 1 point size.
  • When submitting, please name your Figure files according to the convention "figure1.jpg", "figure2.tif" etc. (using the correct file extension), and label the figures themselves with the name of the corresponding author and the figure number (jones_fig1, etc.).
  • 'Box style' figures are not in keeping with the Journal style; line drawings, etc., must have only left-hand and bottom axes.
  • Please note that text, tables (usually) and legends to figures can be corrected by the Press Editors, but figures requiring changes need to be returned to the author for correction and re-submission.

See: http://authorservices.wiley.com/bauthor/illustration.asp for full details on preparing artwork.

That concludes the list of items that should be included in the Manuscript Submission Word Document.

FURTHER INFORMATION

PEER REVIEW AND PUBLICATION PROCESS

The journal operates a single-blind peer-review process using a body of expert peer reviewers; papers are normally reviewed by one Senior Editor, one Editor and three reviewers. Correspondence related to published research in BJP is not usually subject to peer review, but is shared with the authors of the original paper prior to any publication, with a right to reply. All substantive papers — i.e. original research, reviews (commissioned and non-commissioned), including those published under our open access programme OnlineOpen — undergo the same rigorous and consistent peer review process.

Once submitted, a manuscript will first be checked by the Editorial Office to ensure all elements have been submitted. If any required documentation is not present, the Editorial Office will return the manuscript to the authors and request any missing information or material.

Manuscripts are then given a first review by a Senior Editor (triage), who may return the manuscript to the authors to avoid delay if (s)he judges that it is out of scope or has little chance of being accepted after review. Otherwise it will be sent for review, usually by an Editor and three referees.

The referees’ comments and Editor’s recommendation will be reviewed by the appropriate Senior Editor, who will communicate the decision to the corresponding author. This process takes one month on average from submission to the initial decision, but can take longer.

Authors may be asked to revise their manuscript before a final decision is made.

Once your paper is accepted, you will be asked by the editorial office to send any outstanding essential material. This will include a request that you create your Tables of Links (to the end of February 2017) or - from March 1st 2017 - apply hyperlinking within the body of your manuscript (just to the main ligands and targets discussed in your article). You will be supplied with full instructions.

Once all material is received, your article moves into production and your paper is then published within a few days on the journal website in the format of the final accepted version (i.e. as a PDF of the Word version). This final accepted version, known as an ‘Accepted Article’ is fully citable. Simultaneously, the accepted paper is re-formatted into the journal style and then the language and scientific content are checked by a Press Editor. The authors are then sent proofs and asked to agree final changes. Finally, the article is published in Early View, and then in an issue of the journal. This can take a couple of weeks but depends on how quickly the authors respond at proof stage.

Transfer to other British Pharmacological Society (BPS) journals

Pharmacology Research & Perspectives is jointly edited on behalf of the BPS and the American Society of Pharmacology and Experimental Therapeutics (ASPET). The Editors of BJP might consider that a submitted manuscript is out of scope and more suitable for consideration by its sister journals British Journal of Clinical Pharmacology ( BJCP) or the open access journal Pharmacology Research & Perspectives. If so, the Editors will offer authors the opportunity to transfer the manuscript to the editorial office of its sister journals for consideration, with no need to reformat the manuscript.

After Acceptance

Video Abstracts

A video abstract can be a quick way to make the message of your research accessible to a much larger audience.
In 2017, Wiley, our Publishers, and its partner Research Square, will be offering, on a trial basis, a service of professionally produced video abstracts, available to authors of 5 articles selected by the journal. You can learn more about it at www.wileyauthors.com/videoabstracts . Authors of papers selected for this service will be contacted through the editorial office.

Accepted Articles

Within days of acceptance in BJP, manuscripts are made available online as 'Accepted Articles' – an unedited but peer reviewed version of a manuscript. They have not been subject to copy or press-editing, composition or proof correction, so do not have the professional appearance of the final article, but they are citable. This service provides for the earliest possible dissemination of research data following article acceptance.

Accepted Articles appear in PDF format only and are given a Digital Object Identifier (DOI), which allows them to be cited and tracked. The DOI remains unique to a given article in perpetuity and can continue to be used to cite and access the article following its publication in an issue of the Journal in its final format. More information about DOIs can be found online at http://www.doi.org/faq.html. Accepted Articles are indexed in PubMed.

Press editing and Copy-editing are carried out after publication of the Accepted Article. In rare occasions, it is possible that the press edit will identify some fundamental concern regarding the research article, which may require further action with respect to additional editorial changes to be implemented by the authors. If the editorial intervention results in identifying irredeemable problems with the article then the authors and Editorial team may decide that a retraction is required. Neither the British Pharmacological Society nor John Wiley & Sons Ltd. can be held responsible for errors or consequences arising from the use of information contained in Accepted Articles; nor do the views and opinions expressed necessarily reflect those of the British Pharmacological Society or John Wiley & Sons Ltd.

Early View and publication in an issue

Following publication as an Accepted Article, manuscripts are press edited and, after any required changes have been made, are then sent for typesetting. Page proofs will be sent electronically to the corresponding author, who will receive an e-mail alert containing a link to a secure web site for the proofs. A working e-mail address must therefore be provided for the corresponding author. In the absence of the corresponding author, please arrange for a colleague to access the e-mail to retrieve the proofs. Please note that you (i.e. ALL authors) have final responsibility for what is stated in the proofs of your manuscript.

Corrections to the proofs must be returned within 3 days of receipt and instructions on how to do so will be provided in the email. Significant textual alterations are unacceptable at proof stage without the written approval of the Editor, and they are likely to result in the delay of publication. Authors should not make changes to the nomenclature at proof stage.

Fully reviewed, revised and edited articles (except for Letters) will appear as Early View papers around 45 days after acceptance in BJP and can be found in the Early View section of the Wiley Online Library. Early View articles replace the Accepted Article and are complete full-text articles published online in advance of their publication in an issue. They are complete and final, and because they are in final form (fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated), no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. Early View articles are then usually assigned to the next available issue of the journal.

The DOI of the article will remain the same from Accepted Article, through to Early View, to publication in an issue, and can continue to be used to cite and access the article.

The date of publication of the article is the date of its first appearance online as an Accepted Article.

PUBLISHING YOUR PAPER OPEN ACCESS

BJP has no publication or colour charges, but authors are able to publish open access if they so wish.

OnlineOpen, Wiley’s open access programme , is available to BJP authors who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via the journal website, as well as deposited in the funding agency's preferred archive. Please see here for a helpful guide to compliance. See here for open access policies by funder.

Prior to acceptance, there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the Journal's standard peer-review process and will be accepted or rejected based on their own merit. Any authors wishing to send their paper OnlineOpen will be required to complete the payment form.

Copyright: Using the Wiley Author Licensing Service

The author identified as the formal corresponding author for an accepted paper will, on acceptance of their article, receive an email prompting them to login into Author Services, where, via the Wiley Author Licensing Service (WALS), he/she will be able to complete the relevant copyright or licence agreement on behalf of all authors on the paper.

Once inside WALS, there will be full, clear guidance.

Authors choosing OnlineOpen will have to sign a Creative Commons Licences

If a corresponding author selects the OnlineOpen option and his/her research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) he/she will be given the opportunity to publish the article under a CC-BY licence supporting compliance with Wellcome Trust and Research Councils UK requirements. For more information on funder policies, see here and here.

Authors and ORCID

Authors are strongly encouraged to associate their submissions with an ORCID iD (please see this instructional PDF and how to video for guidance). ORCID provides a persistent digital identifier for individual researchers that, through integration in key research workflows such as manuscript and grant submission, supports automated links between a researcher and his/her professional activities, ensuring that his/her work is recognised. On submission, you will be given an opportunity to link your ORCID number with your Scholar One account. There is more information see here and here.

Author Services

Wiley’s Author Services platform allows authors to track the production status of their article, opt in to OnlineOpen, and gain free access to their final published article and share the free access with up to 10 colleagues.

PUBLICATION ETHICS

BJP has a strict and comprehensive Publication Ethics Policy [based on recommendations by the Committee of Publication Ethics (COPE) and Wiley’s Publication Ethics Guidelines], and standard rules on authorship, originality of publication, conflicts of interest and disclosure apply

BJP reserves the right to scrutinise extremely carefully papers submitted by authors with a proven recent breach of our publication ethics code of conduct.

Originality of material

Submission of a manuscript to BJP will be taken to indicate that

  • the content of the manuscript is original and that it has not been published or accepted for publication, either in whole or in part, other than as short abstracts, communications or conference proceedings;
  • no part of the manuscript is currently under consideration for publication elsewhere;
  • all authors have seen and approved the final version of the submitted paper;
  • authors have, if necessary, obtained permission to publish from their employers or institutions;
  • approvals are held from any persons acknowledged, or cited as having provided personal communication;
  • permission has been obtained to use any copyrighted material, such as reproducing a figure from another article, in print and electronic forms, and that the source of the material has been acknowledged; and
  • images have not been manipulated outside the CLIP principles.

All authors should be aware that submissions are scanned for plagiarism through the iThenticate® anti-plagiarism software.

Authorship

All authors of research articles only must indicate their specific contributions to the work presented, and they must do so in an Authorship Contribution Statement. Authors must fulfil all four of the following criteria (see BJP’s Ethics Policy and Wiley’s guidance on authorship ):

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Authors of review articles need not submit an Authorship Contribution Statement, nor state their specific contributions.

Funding

Authors must declare all forms of funding via Funding Statement in the Acknowledgements section of their manuscript.

Examples:

  • This work was supported by a grant from the National Institutes of Health, USA (DKxxxx to AB).
  • This work was supported by the NIH (grant to AB and CD).
  • This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.

Conflicts of Interest

Authors must declare any potential conflicts of interest.

Papers will not be rejected because there is a competing interest: the aim of funding and conflicts of interest statements is not to eradicate conflicts of interest (they are common); it is so that BJP articles are fully transparent and ethical.

A conflict of interest exists when a primary interest (such as the validity of research) might be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors of a BJP article when they have a financial interest that may influence their interpretation of their results or those of others. Financial interests are the easiest to define and they have the greatest potential to influence the objectivity, integrity or perceived value of a publication. They may include any or all, but are not limited to, the following:

  • Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultant or speaker fees; other forms of remuneration from organisations that may gain or lose financially; patents or patent applications whose value may be affected by publication.
  • Employment: Recent, present or anticipated employment of you or a family member by any organization that may gain or lose financially through publication of the paper.
  • Gifted drugs, materials or devices not commercially available
  • Patent rights
  • Consultancy work (past or present).

For papers where no conflicts of interest or funding are declared, a default statement is added to that paper.

For the Journal’s policy on publication misconduct and other all areas of publishing ethics, please see the Journal’s Ethics Policy .

Contacting the Journal with expressions of concern

BJP is dedicated to correcting errors in the scientific literature – be they errors in data, statistical analysis or of an ethical nature - and doing so quickly, in line with COPE guidelines. As such, please send expressions of concern over BJP published material direct to the journal’s Executive Editor at the Publishers, ldeakin@wiley.com. Please see the journal’s comprehensive publication ethics policy for full details.

These Author Guidelines were last updated on 7th February 2017.

SEARCH

SEARCH BY CITATION